Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Publikováno v:
Investigational New Drugs; Jun2021, Vol. 39 Issue 3, p705-712, 8p
Autor:
Sardesai, Sagar, Badawi, Mohamed, Mrozek, Ewa, Morgan, Evan, Phelps, Mitch, Stephens, Julie, Wei, Lai, Kassem, Mahmoud, Ling, Yonghua, Lustberg, Maryam, Stover, Daniel, Williams, Nicole, Layman, Rachel, Reinbolt, Raquel, VanDeusen, Jeffrey, Cherian, Mathew, Grever, Michael, Carson, William, Ramaswamy, Bhuvaneswari, Wesolowski, Robert
Publikováno v:
Investigational New Drugs; Oct2020, Vol. 38 Issue 5, p1400-1410, 11p
Autor:
Cueva, Juan, Calvo, Marcos, Anido, Urbano, León, Luis, Gallardo, Elena, Areses, Carmen, Bernárdez, Beatriz, Gayoso, Lucía, García, Jorge, Jesús Lamas, María, Curiel, Teresa, Vázquez, Francisca, Candamio, Sonia, Vidal, Yolanda, Javier Barón, Francisco, López, Rafael
Publikováno v:
Investigational New Drugs; Apr2012, Vol. 30 Issue 2, p688-694, 7p
Autor:
Lecarpentier, Edouard, Ouaffi, Lamia, Mir, Olivier, Berveiller, Paul, Maurel, Melinda, Pujade-Lauraine, Eric, Bouillot, Jean, Veyrie, Nicolas
Publikováno v:
Investigational New Drugs; Dec2011, Vol. 29 Issue 6, p1500-1503, 4p
Autor:
Sally Tan, Pasi A. Jänne, John J. Wright, Katherine Larrabee, Hao Guo, Eric P. Winer, Sara M. Tolaney, Eliezer M. Van Allen, Elena Ivanova, Ian E. Krop, Beth Overmoyer, William H. Barry, Jane E. Brock, Geoffrey I. Shapiro, Cloud P. Paweletz, Nikhil Wagle
Publikováno v:
Investigational New Drugs
SummaryBackground MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests t